

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	10130775
<b>Application Number:</b>	10576981
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8112
<b>Title of Invention:</b>	Method Of Therapy
<b>First Named Inventor/Applicant Name:</b>	Martin Leonard Ashdown
<b>Customer Number:</b>	22442
<b>Filer:</b>	Robert D. Traver
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	5517-18
<b>Receipt Date:</b>	19-MAY-2011
<b>Filing Date:</b>	02-MAR-2007
<b>Time Stamp:</b>	19:03:56
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1270
RAM confirmation Number	5226
Deposit Account	191970
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Response_to_Final_OA.pdf	763377	yes	30
			38a670d74e1bb0c4f260c365690bd97c781c9203		

### Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Amendment/Argument after Notice of Appeal	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	30

### Warnings:

### Information:

2	Affidavit/Dec/Exhibit after Notice of Appeal	Dec_of_Coventry.pdf	282276	no	6
			b75cd44eb205325a651369dac9756cc89d09cd9d		

### Warnings:

### Information:

3	Request for Continued Examination (RCE)	RCE.pdf	81960	no	1
			ba2989d30474c114dfa38ec9164d420d0f97927d		

### Warnings:

This is not a USPTO supplied RCE SB30 form.

### Information:

4	Information Disclosure Statement (IDS) Filed (SB/08)	IDS_08.pdf	283473	no	6
			80f54980f53ce7df7775a852dd9463485f870905		

### Warnings:

### Information:

This is not an USPTO supplied IDS fillable form

5	NPL Documents	ANDERSON_Effects_of_Cyclophosphamide_and_Irradiation.pdf	558130	no	7
			a3d996525dca2ccb8ad1a22a04e6fd26d17019d4		

### Warnings:

### Information:

6	NPL Documents	BALINT_Immune_complexes_with_antiglobulin_activity.pdf	540658	no	9
			f6ba993ac84bf6e5c15681559afe168f6e3c10e9		
Warnings:					
Information:					
7	NPL Documents	BARRETT_Undulations_in_the_Time-Response_Curve.pdf	1750540	no	7
			9908d3b6e01738cbbef031e0370797c993883871		
Warnings:					
Information:					
8	NPL Documents	BORJABAD_etal_Gene_Expression_Profiles_of_HIV-1-Infected.pdf	4646991	no	19
			c1259549794e9164ca429d9ccf3cd7209e6427a		
Warnings:					
Information:					
9	NPL Documents	CHAN_etal_Quantitative_Analysis_of_Human_Immunodeficiency_Virus.pdf	4111609	no	13
			2e5bcf91d14d1615b8434597ea1207005557aacf		
Warnings:					
Information:					
10	NPL Documents	COVENTRY_CRP_identifies_homeostatic_immune.pdf	749980	no	8
			53b8709e3b8c75821290503a4261251b671ea54f		
Warnings:					
Information:					
11	NPL Documents	DENHAM_The_Occurrence_of_Two_Types.pdf	2356487	no	17
			18226cee55a394e2e91347382209f8c1ae2cdf4f		
Warnings:					
Information:					
12	NPL Documents	MING_Studies_on_development_of_treatment_against_retroviruses.pdf	663772	no	4
			94e757e7258dd9bb349275ca0454674692e8b876		
Warnings:					
Information:					
13	NPL Documents	NORTH_The_Murine_Antitumor.pdf	7430199	no	67
			f2da9559811cf3d51c48ffb3fd2466c296e16147		
Warnings:					
Information:					
14	NPL Documents	NORTH_Generation_and_Decay.pdf	1797387	no	17
			893bfa465c1ecaa643326deae1e70aa47b7aa7f5		
Warnings:					
Information:					

15	NPL Documents	OBRIEN_etal_Changes_in_Plasma_HIV-1_RNA.pdf	611812	no	6
			7dceefe0a9bb2f9945ed2f5d35e13fadd3c23545		
Warnings:					
Information:					
16	NPL Documents	QUEVEDO_Possible_Therapeutic_Reversal.pdf	139420	no	1
			fbbf7fad54c77d5b39f8f83af656f0bc4711fb9e		
Warnings:					
Information:					
17	NPL Documents	Simpson_Cell-Mediated_Responses.PDF	774516	no	6
			45ff161aeb28815915a25345596579ee9c72aded		
Warnings:					
Information:					
18	NPL Documents	CN01817380_OA_referencing_Ming_Meng.pdf	341229	no	8
			9b2689c2c42130644109d3e8166204add3e164e6		
Warnings:					
Information:					
19	NPL Documents	AU_Exam_Report_in_2004283322_01Jul2010.pdf	152104	no	3
			9224369584ff998ce1aba30ba9385d115b51e962		
Warnings:					
Information:					
20	NPL Documents	AU_Request_Amend_Spec_in_2004283322_22Jun2010.pdf	1301630	no	30
			39a175e63b7b7f313ee872b2383c6e216af77670		
Warnings:					
Information:					
21	NPL Documents	CN_OA_in_2004800389993_24Apr2009_with_English_translation.pdf	492620	no	9
			19305fa04b165b3e0dfe534ede261527e5828142		
Warnings:					
Information:					
22	NPL Documents	EP04761461_OA_12-17-2008.pdf	395274	no	7
			bf72492487445faace6369971da9366fe2f14549		
Warnings:					
Information:					
23	NPL Documents	EP_Comm_Art94_in_04761461_07Aug2009.pdf	392520	no	8
			b25bdaf53c7bbd2844d7fe5da7c3483ede81b105		
Warnings:					
Information:					

24	NPL Documents	EP04761461_OA_08-07-2009.pdf	531473	no	8
			3636b458316cf9c04f5e436ffa58f3d095b1153		
Warnings:					
Information:					
25	NPL Documents	EP04761461_OA_02-24-2010.pdf	923798	no	15
			f49ee3a533f19948876457bf4ed99ef66b456f40		
Warnings:					
Information:					
26	NPL Documents	EP04761461_OPM_07-02-2010.pdf	1834123	no	29
			a64d21a567719f9a3f39e1307fb4233bcc5df3fe		
Warnings:					
Information:					
27	NPL Documents	JP2006-535913_OA_10-25-2010.pdf	668552	no	10
			4c60aab5ddc2a2b76074ae2d633fb89781436145		
Warnings:					
Information:					
28	NPL Documents	MXPAa2006004522_OA_5-18-2009.pdf	272094	no	4
			198c11ac43d60c236d1fa5b261be05f42e935db0		
Warnings:					
Information:					
29	NPL Documents	MXPAa2006004522_OA_11-09-2009.pdf	149120	no	2
			15f497b87bbfc0791646d8e5090da0232f74da5e		
Warnings:					
Information:					
30	NPL Documents	MXPAa2006004522_OA_03-23-2010.pdf	149347	no	3
			a6fb4a9a5b37b58e9b9a330878dc4632d52355fe		
Warnings:					
Information:					
31	NPL Documents	NZ_Exam_Report_in_546873_04Dec2007.pdf	204010	no	2
			398da2ac86ace45cf3614d325df6315cc8f5f3c		
Warnings:					
Information:					
32	NPL Documents	NZ_Exam_Report_in_546873_30Sep2009.pdf	136721	no	2
			5d6a8c92af096d6a2eb7e53038a0ced6ee7f15a5		
Warnings:					
Information:					

33	Fee Worksheet (PTO-875)	fee-info.pdf	31854	no	2
			f4f335a593512dda3b69f13581ee0077610f7ead		
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				35519056	
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					